title: The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.
abstract: Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDCA), has permeation-enhancing effects. Sodium alginate (SA) was used to microencapsulate G and CDCA to produce control (G-SA) and test (G-CDCA-SA) microcapsules. Both microcapsules showed uniform structure, morphology, and good stability profiles. CDCA reduced G-release at pH 7.8, while G-release was negligible at lower pH values in both microcapsules. CDCA incorporation resulted in less swelling and stronger microcapsules, suggesting improved stability.
authors.affiliation: a Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, School of Pharmacy, Curtin University , Perth WA , Australia.
authors.forename: Sangeetha
authors.initials: S
authors.lastname: Mathavan
authors.affiliation: b Faculty of Science and Engineering, Curtin University , Perth WA , Australia.
authors.forename: Nigel
authors.initials: N
authors.lastname: Chen-Tan
authors.affiliation: c Curtin Health Innovation Research Institute, Biosciences Research Precinct, School of Biomedical Sciences, Curtin University , Perth WA , Australia.
authors.forename: Frank
authors.initials: F
authors.lastname: Arfuso
authors.affiliation: a Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, School of Pharmacy, Curtin University , Perth WA , Australia.
authors.forename: Hani
authors.initials: H
authors.lastname: Al-Salami
mesh_terms: D000284:Administration, Oral; D000464:Alginates / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D002214:Capsules; D002635:Chenodeoxycholic Acid / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004339:Drug Compounding; D005907:Gliclazide / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D020723:Glucuronic Acid / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006603:Hexuronic Acids / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D000464:Alginates; D002214:Capsules; D006603:Hexuronic Acids; D007004:Hypoglycemic Agents; D002635:Chenodeoxycholic Acid; D020723:Glucuronic Acid; D005907:Gliclazide
keywords: artificial cell microencapsulation; bile acids; chenodeoxycholic acid; diabetes; gliclazide